The Tax I trans-activator protein of the human T-cell leukemia virus I (HTLV-I) enhances viral gene expression through enhancer sequences in the viral LTR. These sequences consist of three imperfect 21-bp repeats (TRE-1) and a region between the promoter central and promoter proximal TRE-1 (known as TRE-2). We have previously described the in vivo footprint of the HTLV-I TRE-1s and TRE-2 in two HTLV-I-infected cell lines, MT-2 and MT-4. MT-2 is a high-level producer of virus and shows significant DNA-protein interactions within the TRE-1s and TRE-2. In contrast, the proviral DNA in MT-4 cells is heavily methylated and produces no detectable virus. In this report, we describe the footprints of the TRE-1s and TRE-2 in MT-4 cells that were induced to express high levels of viral proteins by treatment with 5-azacytidine, a potent inhibitor of methylation. The footprints of the TRE-1s in 5-azacytidine-treated MT-4 cells were virtually identical to those observed in MT-2 cells. In contrast, the footprints within the TRE-2 region of 5-azacytidine-treated MT-4 cells did not resemble those in either MT-2 or MT-4 cells.
INTRODUCTION
The human T-cell leukemia virus I (HTLV-I) is the etiological agent of an aggressive leukemia known as adult T-cell leukemia (Poiesz et al., 1980; Yoshida et al., 1982) and a neurological disorder known as HTLV-I-associated myelopathy/tropical spastic paraperesis (Gessain et al., 1985; Osame et al., 1986) . The Tax I protein of HTLV-I is a virus-coded trans-activator that enhances viral gene expression through target sequences in the U3 region of the viral long terminal repeat (LTR) (Fujisawa et al., 1985 (Fujisawa et al., , 1986 Sodroski et al., 1984) . It is believed that Tax I enhances transcription by interacting with cellular transcription factors that specifically bind the target DNA sequences in the viral LTR. These sequences consist of three imperfect 21-bp repeats, known as TRE-1s, and a region between the promoter central and promoter proximal TRE-1, known as TRE-2 ( Fig. 1) (Brady et al., 1987; Fujisawa et al., 1986; Marriott et al., 1989; Miwa et al., 1984; Paskalis et al., 1986; Rosen et al., 1985 Rosen et al., , 1987 Shimotohno et al., 1986) . MT-4 and MT-2 are human T-cell lines that were generated by cocultivation of cord blood lymphocytes with cells from leukemic HTLV-I-infected patients (Miyoshi et al., 1981) . MT-4 cells produce low/undetectable levels of HTLV-I, while MT-2 cells are high-level producers of the virus (Koyanagi et al., 1984) . We previously used in vivo footprinting to show that HTLV-I LTRs in MT-4 cells do not show any appreciable DNA-protein interactions within the TRE-1s and only weak interactions within the TRE-2 (Datta et al., 2000) . In contrast, the MT-2 cells show significant DNA-protein interactions within the TRE-1s and the TRE-2 (Datta et al., 2000) .
Other investigators have shown that the low level of viral gene expression in MT-4 cells is due to extensive methylation of the proviral DNA (Saggioro et al., 1990) . Moreover, treatment of these cells with 5-azacytidine, a potent inhibitor of DNA methylation, results in induction of viral expression (Saggioro et al., 1990) . In this report, we have exploited the inducibility of HTLV-I expression in MT-4 cells to further investigate the effects of Tax I expression on DNA-protein interactions within the HTLV-I LTR. We performed genomic in vivo footprinting of the HTLV-I LTRs in MT-4 cells after treatment with 5-azacytidine. The results indicated that the 5-azacytidine induction was accompanied by an increase in Tax I activity and also an increase in proteins bound to the HTLV-I enhancer sequences.
RESULTS AND DISCUSSION
We first investigated the effect of 5-azacytidine on Tax I expression. It has been reported that maximal viral gene expression in MT-4 cells is seen 12 days after treatment with 5-azacytidine (Saggioro et al., 1990) . In initial experiments, we confirmed induction of HTLV-I expression upon 5-azacytidine treatment of MT-4 cells, but in our experiments, maximal levels of Tax I RNA and protein were observed 6 days after treatment with 5 mM 5-azacytidine (data not shown). We tested if the increase in the levels of Tax I RNA and protein also were reflected in an increase in the levels of biologically active Tax I in a transient transfection assay of 5-azacytidine-treated MT-2 and MT-4 cells using a reporter plasmid containing the secreted alkaline phosphatase gene under the control of the HTLV-I LTR (Fig. 2) . MT-2 cells did not show any change in their ability to support high-level expression of the HTLV-I LTR after treatment with 5-azacytidine ( Fig.  2A) . In contrast, MT-4 cells showed an approximately fourfold increase in their ability to express the HTLV-I LTR after treatment with 5-azacytidine ( Fig. 2B ), indicative of higher levels of biologically active Tax I.
While the most likely explanation for the results of Fig.  2 was activation of the resident HTLV-I proviruses in the MT-4 cells by 5-azacytidine treatment, it was also possi-ble that the increase in Tax I activity was due to reinfection of the MT-4 cells by induced HTLV-I virions, followed by integration into more transcriptionally active parts of the genome. To address this possibility, we also tested reporter activity in MT-4 cells after treatment with 5-azacytidine in the presence of AZT at concentrations that would block new rounds of viral infection (Macchi et al., 1997) (Fig. 2B ). MT-4 cells showed essentially the same 5-azacytidine induction of the HTLV-I LTR activity in the presence or absence of AZT ( Fig. 2B ). Treatment with AZT alone resulted in an approximately 50% drop in the reporter activity in MT-4 cells. This indicated that the 5-azacytidine treatment did not result in substantial new rounds of viral infection during the times studied here.
These data collectively demonstrated that treatment of MT-4 cells with 5-azacytidine resulted in an increase in the levels of Tax I RNA (not shown) and biologically active Tax I protein. Further, they also indicated that incorporation of 5-azacytidine into the HTLV-I LTR did not affect its ability to respond to Tax I. We next used 5-azacytidine-treated MT-4 cells to investigate the effect of increasing levels of active Tax I on the in vivo pattern of DNA-protein interactions for the HTLV-I LTR.
We have previously described in vivo footprints of the HTLV-I LTR in MT-2 and MT-4 cells obtained by using in vivo dimethyl sulfate (DMS) methylation followed by ligation-mediated PCR (LMPCR) (Datta et al., 2000) . In this technique, live cells are exposed to DMS at concentrations that will partially methylate accessible guanine residues within the genome. DNA is then extracted from these cells and cleaved at methylated guanine residues with piperidine; the cleavage pattern of the DNA within the HTLV-I LTR is analyzed by ligation-mediated PCR using nested LTR-specific primers. This technique generates a G-ladder of the sequence of interest; in vivo protections or hypersensitivities to DMS methylation of these guanine residues are deduced by comparing the relative methylation of a guanine residue in in vivo DMStreated DNA to DNA that has been exposed to DMS after being extracted from the same cells (in vitro). Using this technique we have shown that the CREs in all three TRE-1s in MT-2 cells are occupied to varying degrees, with the promoter proximal TRE-1 showing the strongest interactions (as judged by the degree of protection or hypersensitivity) (Datta et al., 2000) . In contrast, MT-4 cells showed no evidence of protein binding within the TRE-1s and only weak interactions within the TRE-2 (Datta et al., 2000) .
Before performing in vivo DMS footprinting on 5-azacytidine-treated MT-4 cells, we first investigated whether the drug had any general effects on the signal obtained by in vitro DMS footprinting and LMPCR (Fig. 3) . The signal from a standard LMPCR reaction on in vitro DMStreated and piperidine-cleaved DNA from MT-4 and MT-2 cells grown in the absence of 5-azacytidine is shown in Fig. 3 (lane c, MT-4; lane f, MT-2). The LMPCR signal from the same DNA samples after cleavage with piperidine but without DMS treatment is shown in lane b (MT-4) and lane e (MT-2). Piperidine cleavage without prior DMS treatment produced a low-level signal at all nucleotides; this is probably reflective of a low-level degradation of the DNA templates and the sensitivity of the LMPCR assay. Surprisingly, piperidine cleavage without prior DMS treatment on DNA from 5-azacytidine-treated MT-4 cells produced strong bands that corresponded to the cytosine residues in the sequence (lane a). This suggests that piperidine can cleave DNA at 5-azacytidine residues. For reference, the signal from a standard LMPCR reaction on in vitro DMS-treated and piperidinecleaved DNA from MT-2 cells grown in the presence of 5-azacytidine is shown in lane d. DNA from 5-azacytidine-treated MT-2 cells also showed pronounced bands at C residues in addition to the expected bands at G (guanine) residues upon LMPCR compared to DNA from cells not treated with 5-azacytidine (lane d).
We also investigated the effects of 5-azacytidine incorporation on the in vivo DMS-footprinting/LMPCR procedure. In order to do this we compared the results of in vivo footprinting of MT-2 cells grown in 5-azacytidine to our previously reported footprints for MT-2 cells. The results of such an analysis on the lower strand of the promoter central TRE-1 are shown in Fig. 4A . The bands corresponding to C residues in the TRE-1 have been marked with asterisks. Arrows pointing toward the gel designate hypersensitivities (as in Fig. 5 ) and arrows pointing away indicate protections. The footprint observed for the promoter-central TRE-1 in 5-azacytidinetreated MT-2 cells is compared to our previously reported footprint for the same TRE-1 in untreated MT-2 cells (Datta et al., 2000) in Fig. 4B . In parallel with our observation that there was no change in the reporter activity of MT-2 cells grown in the presence of 5-azacytidine (Datta et al., 2000) , there was also no change in the footprint from that observed previously. We also did not observe any change in the footprints of the other two TRE-1s and the TRE-2 from their patterns in untreated cells (not shown). These data suggest that besides that DNA could be cleaved by piperidine at 5-azacytidine residues, there were no fundamental changes in the footprint when 5-azacytidine was incorporated into the DNA.
The in vivo footprints of the lower strand of the TRE-1s
in 5-azacytidine-treated MT-4 cells are shown in Fig. 5 . In this report, we concentrated on the lower strand of the LTR since it is very G-rich and, therefore, more informative than the upper strand in this assay. The guanine residues in each TRE-1 have been numbered. The intensity of each guanine residue in the in vivo sample was compared to the intensity of the cognate guanine in the in vitro sample by phosphorimager quantification. The Fig. 4A . The G residues in the sequences are numbered. Arrows pointing away from the gel indicate protected residues; arrows pointing toward the gel indicate hypersensitive residues. Large arrowheads indicate major protected or hypersensitive residues. C residues are denoted by asterisks. Footprints of the three TRE-1s are summarized along with the footprints previously reported for untreated MT-2 and MT-4 cells (Datta et al., 2000) . The same conventions as described in the legend to footprints of the TRE-1s in 5-azacytidine-treated MT-4 cells are also summarized, along with the patterns we previously reported for MT-2 cells and MT-4 cells (Datta et al., 2000) in the absence of 5-azacytidine in Fig. 5 . Most importantly, in 5-azacytidine-treated MT-4 cells, footprints were evident in each of the TRE-1s, in contrast to the absence of footprints over these sequences in MT-4 cells grown in regular medium. Moreover, MT-4 cells treated with 5-azacytidine showed very similar footprints to those of MT-2 cells. All 17 of 26 total guanine residues in the three TRE-1s that were protected or hypersensitive in MT-2 cells were also correspondingly protected or hypersensitive in 5-azacytidine-treated MT-4 cells. The only differences observed between the footprints were a protection of the G1 and G2 guanines in the promoter distal TRE-1 and a protection of the G7 guanine in the promoter central TRE-1 that had not been observed in MT-2 cells (Datta et al., 2000) . These data suggest that the footprints in MT-2 and 5-azacytidinetreated MT-4 cells are very likely caused by the same (or similar) protein complex(es). In vitro, the TRE-1s can be bound by several members of the CREB-ATF family of transcription factors or also jun family transcription factors (Jeang et al., 1988; Nyborg et al., 1990; Tan et al., 1989; Tsujimoto et al., 1991; Yin and Gaynor, 1996a,b; Yoshimura et al., 1990; Zhao and Giam, 1992) . Indeed, it has been shown that in vitro, Tax I enhances the dimerization and DNA binding of both CREB-ATF and Jun proteins (Wagner and Green, 1993) . Thus, the observation that identical footprints are observed in both cell lines suggests that Tax I expression in vivo results in preferential loading of the same transcription factors onto the TRE-1s in MT-2 and 5-azacytidine-treated MT-4 cells, since it seems unlikely that all the proteins that can potentially bind the TRE-1s would yield the same in vivo footprint.
Lastly, we analyzed the lower strand of the TRE-2 in 5-azacytidine-treated MT-4 cells (Fig. 6 ). MT-2 and MT-4 both show evidence of DNA-protein interactions within the TRE-2 region (Datta et al., 2000) . However, the footprints are different, suggesting that a different protein(s) is bound to the sequences in the two cell lines. MT-2 cells show very strong protections spanning several putative factor-binding sites in the TRE-2, while MT-4 cells show two hypersensitivities within this region and much less extensive protections (Datta et al., 2000) . It was interesting that in 5-azacytidine-treated MT-4 cells, the TRE-2 footprint shifted to a pattern that resembled neither MT-2 nor MT-4 cells. The two hypersensitive guanines observed in MT-4 cells at G7 and G11 (Datta et al., 2000) were also present in 5-azacytidine-treated MT-4 cells; also, G11 was strongly hypersensitive only in 5-azacytidine-treated cells. In contrast, MT-2 cells are protected at the G7 residue and hypersensitive at the G11 residue. The AP-2/PEA-3 binding sites also showed more extensive protections in 5-azacytidine-treated MT-4 FIG. 6. In vivo DMS footprinting of the lower strand of the TRE-2 in 5-azacytidine-treated MT-4 cells. In vivo footprinting was performed as in Fig.  5 . The predicted binding sites for different transcription factors are indicated. The footprint of the TRE-2 is summarized along with the footprints previously reported for untreated MT-2 and MT-4 cells (Datta et al., 2000) . The same conventions as described in the legend to Fig. 5 are used. cells. All of the G residues in this region (G1-G6) were protected, and G6 and G2-G4 were strongly protected. MT-2 cells, however, were hypersensitive at G4. Also, three guanine residues (G7-G9) spanning the 5Ј end of the predicted NF-B binding site showed indications of DNA-protein interactions. The pattern in this region resembled MT-2, except that G7, which is protected in MT-2 cells, remained strongly hypersensitive in 5-azacytidine-treated MT-4 cells. The remaining G residues in the NF-B region (G10-G13) showed an MT-2-like pattern, although the relative intensities of the bands were different. The footprints of the TRE-2 are also summarized in Fig. 6 along with the patterns we previously reported for MT-2 and MT-4 cells (Datta et al., 2000) . These data indicated that unlike the TRE-1s, the TRE-2 displayed a footprint that was unlike MT-2 or MT-4; instead, the footprint observed was a hybrid between the two cell lines.
It has been reported that the TRE-2, in conjunction with least one TRE-1, is capable of imparting Tax I responsiveness to the HTLV-I LTR in vitro (Numata et al., 1991) . This has led to the suggestion that the TRE-2 is a target of Tax I in the activation of the HTLV-I LTR in vivo (Numata et al., 1991) . However, the absence of a complete shift of the TRE-2 footprint to a MT-2 like pattern raises the possibility that the TRE-2 sequences may not be essential for Tax I-mediated activation of the HTLV-I LTR in vivo, at least in MT-4 cells induced by 5-azacytidine. This is even more striking given that the TRE-1 footprints were completely converted to a MT-2-like footprint. One possible explanation for the difference between the conclusions of the previous studies and those of ours could be that our in vivo footprinting studied integrated proviral DNA in the context of chromatin, while the previous studies used transient transfection assays in which the transcribed DNA is not in native chromatin.
One potential criticism of our in vivo footprinting experiments could be that only a subset of the HTLV-I proviruses were transcribed in the 5-azacytidine-treated MT-4 cells; thus, the TRE-2 footprint might reflect inactive rather than active proviruses. However, both MT-2 and MT-4 cells contain approximately seven proviruses each (Cavrois et al., 1995; Kobayashi et al., 1984) , at least one of which is full length. In addition, six of seven defective proviruses in MT-2 cells are capable of Tax I expression . Since 5-azacytidine-treated MT-4 cells express similar levels of Tax I RNA and protein compared to MT-2 cells (unpublished observations), it seems likely that most of the proviruses in these two cells are being transcribed. Also, the appearance of protections and hypersensitive sites in the TRE-1s after 5-azacytidine induction of MT-4 cells indicated that the chromatin configuration of a substantial number of the HTLV-I proviruses had changed. It should also be noted that the analysis of the lower strand (Fig. 5) combined signals from both the upstream and downstream LTRs.
Thus, in the case of the strongest protections (e.g., the central G residues in the TRE-1s), this might indicate factor binding in both LTRs after 5-azacytidine treatment.
Taken together, these facts support the argument that the dissimilarities in the TRE-2 footprints between 5-azacytidine-treated MT-4 and MT-2 or untreated MT-4 cells are probably significant. However, considering that the MT-2 cells show strong DNA-protein interactions within the TRE-2 (Datta et al., 2000) , it is possible that the TRE-2 may be involved in Tax I-mediated activation of the HTLV-I LTR only upon sustained expression of Tax I. We were unable to test this possibility because 5-azacytidine is toxic and the cells cannot be maintained in medium containing the drug for extended periods.
In summary, we have demonstrated in this report that treatment of MT-4 cells with 5-azacytidine results in activation of viral expression, an increase in biologically active Tax I, and a change in DNA-protein interactions within the HTLV-I LTR in vivo. The footprints within the TRE-1s are strikingly similar to those seen in highly expressing MT-2 cells. In contrast, the footprints within the TRE-2 of 5-azacytidine-treated MT-4 cells did not resemble those of MT-2 or MT-4 cells. Instead, they resembled a hybrid between MT-2 and MT-4 cells at the predicted AP-2 and NF-B binding sites. These results are consistent with our previous suggestion that the in vivo footprints seen within the TRE-1s reflect Tax I-dependent loading of transcription factors. Further, they raise the possibility that the TRE-2 may not be essential for 5-azacytidine-induced Tax I-mediated activation of the HTLV-I LTR in vivo in the context of chromatin.
MATERIALS AND METHODS

Cell lines
In vivo footprinting was performed on the MT-4 and MT-2 cell lines (Miyoshi et al., 1981) , both human T-cell cell lines isolated from cord blood lymphocytes that were cocultured with leukemic cells from patients with HTLV-I-associated adult T-cell leukemia. The NIH AIDS Reagent Program provided the MT-4 and MT-2 cells. The cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum. For 5-azacytidine treatment, MT-4 cells were grown in medium containing 5 M 5-azacytidine for 6 days before DMS treatment.
Transfections and reporter assays
MT-2 or MT-4 cells were cotransfected with pHTLV-I LTR-SEAP (a reporter plasmid containing the HTLV-I LTR driving the secreted alkaline phosphatase reporter gene) and pRL-null (a promoter-less Renilla luciferase reporter plasmid; Promega) as described previously (Datta et al., 2000) . Details on the construction of pHTLV-I LTR-SEAP will be provided upon request. The medium was sampled for SEAP activity 72 h posttransfection. SEAP activity was assayed using the Phospha-Light chemiluminescent reporter gene assay kit (Tropix, Inc.) according to the manufacturer's instructions. For treatment with 5-azacytidine or 5-azacytidine plus AZT, MT-4 cells were grown in the presence of 5 M 5-azacytidine or 5 M 5-azacytidine plus 0.02 mM AZT for 3 days. The cells were then transfected with pHTLV-I LTR SEAP and pRLnull and the medium was sampled for SEAP activity 3 days posttransfection.
In vivo footprinting and ligation-mediated PCR
In vivo footprinting visualized by LMPCR was performed essentially as described by Mueller and Wold (1989) , with minor modifications. Detailed descriptions of the procedure and the specific oligonucleotides used for HTLV-I are described in Datta et al. (2000) . Briefly, exponentially growing cells were treated with DMS under conditions that resulted in partial methylation of guanine residues. High-molecular-weight DNA was then extracted from the cells and cleaved to completion with piperidine (at methylated G residues). The cleaved DNA was then subjected to a series of nested PCR-based primer extensions and amplifications using primers specific for the HTLV-I LTR. The final PCR amplification was performed using a 32 P-labeled HTLV-I LTR-specific primer, and the reaction was separated on a sequencing gel and exposed to film or a storage phosphor screen for quantitative analysis. As a control, high-molecularweight DNA was extracted from the cells, subjected to DMS treatment in vitro, and then processed in parallel with the in vivo samples.
